Kidney Failure Clinical Trial
Official title:
ACCESS: Prospective, Multi-center Trial of the Fusion Vascular Access Graft for Patients Who Require Early Vascular Access for Hemodialysis
The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of the Fusion™ Vascular Access Graft for patients in need of early vascular access for hemodialysis.
The Boston Scientific ACCESS trial seeks to study the safety and to evaluate the success of
the Fusion™ Vascular Access Graft for patients in need of early vascular access for
hemodialysis. The primary objective is to demonstrate that secondary patency at 6 months for
the Fusion™ Vascular Access Graft is not less than an objective performance criterion (OPC)
minus a clinically relevant margin (δ). The OPC represents secondary patency at 6 months for
the standard of care access grafts.
The secondary safety endpoint is the occurrence of CEC-adjudicated device or procedure
related adverse events through 24 months post implant procedure, or through discharge for
patients with unsuccessful device implantation. Secondary efficacy endpoints include:primary
patency; primary assisted patency; ability to revise a failed graft; early access
capability; time to hemostasis.
Subjects will undergo a thorough medical assessment and physical examination pre-procedure
and will be assessed peri-procedure. Enrolled subjects with a device implanted will be
evaluated at 1, 6, 12, 18 and 24 months post implant procedure.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
| Completed |
NCT02546037 -
Clotting With Different Dialyzer Membranes
|
||
| Recruiting |
NCT02545920 -
To Assess Ear Blood Flow During Dialysis
|
||
| Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01912001 -
Virtual Ward for Home Dialysis
|
N/A | |
| Completed |
NCT01158742 -
Live Kidney Donor Study -Renal Function Study
|
N/A | |
| Completed |
NCT00986947 -
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
|
Phase 2 | |
| Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
| Withdrawn |
NCT00807274 -
Renal Function in Adults With Congenital Heart Disease.
|
N/A | |
| Completed |
NCT00369382 -
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT00183248 -
Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05324878 -
Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
|
||
| Completed |
NCT05272800 -
BIS-guided Fluid Management in HD Patients
|
N/A | |
| Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
| Completed |
NCT01756508 -
Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury
|
Phase 2 | |
| Completed |
NCT03723668 -
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
|
||
| Recruiting |
NCT04277377 -
Nanoparticle for DSA Removal
|
||
| Terminated |
NCT00450333 -
Dynepo Infrequent Dosing Study
|
Phase 3 | |
| Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT04714853 -
Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins
|